Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
T cell activation is a key event in the adaptive immune system and vital in the generation of protective cellular and humoral immunity. Activation is required to generate CD4 effector T cell responses and provide help for B cell and cytotoxic T cell responses. While defective T responses to foreign antigen result in infectious pathology, over-reactive T cell responses against self-antigens result in autoimmunity and, in a transplantation setting, tissue rejection. Understanding how T cell activation is normally regulated is critical to therapeutic intervention and the CD28/CTLA-4 (CD152) pathway represents the initial activation checkpoint in molecular terms. In particular, while the CTLA-4 pathway is well established as an essential regulator of self-reactivity, its mechanism of action is still uncertain. Such mechanistic issues are important given its central position in T cell activation and the increasing number of therapeutic modalities aimed at manipulating the CD28/CTLA-4 pathway. Here, we provide an updated view of CTLA-4 biology, reviewing the established features of the system and highlighting its interplay with CD28. We then discuss how recent progress in our understanding of this pathway affects our interpretations following intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 1×
“This issue has been convincingly demonstrated by recent experiments using Tregs from CTLA-4-deficient mice (28) or conditionally deficient Tregs (29), which reveal CTLA-4 to be critical for Treg function in the prevention of autoimmunity.”
MethodTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“From a functional perspective, the most striking observation is that in contrast to CD28, where deficiency leads to lack of effective T cell responses, CTLA-4-deficient mice suffer from a fatal overactivated phenotype resulting in profound autoimmunity driven by self-reactive T cells (12,13).”
BackgroundTrans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · cited 1×
“Based initially on observations using cell coculture models we observed that robust transfer of ligands (CD80 and CD86) could occur between ligand-expressing donor cells in contact with CTLA-4 expressing recipient cells (33).”
BackgroundSelf-citationMolecular Basis of T Cell Inactivation by CTLA-4
Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684
Lanier, L. L., O'Fallon, S., Somoza, C., Phillips, J. H., Linsley, P. S., Okumura, K., Ito, D., & Azuma, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.97 · Cited by 480
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194 · cited 1×
“The former strategy of using CD28 costimulation to expand Treg (Figure 2C) was initially behind the ill-fated TGN1412 trial (59), suggesting it is extremely problematic.”
MethodLühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S. J., Hanke, T., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021024 · Cited by 193
Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97 · cited 1×
“However, recent studies have continued to explore this approach and indicate that selective Treg expansion is nonetheless possible with such an approach (60).”
Background
Cited by
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
“ITIM domains (TIGIT) (16) CD4 (including Treg, follicular helper T cells),”
BackgroundInfluentialBaretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Abdel-Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160221 · Cited by 444
Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., et al. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3750 · Cited by 179
“In addition, there are multiple immunomodulators that target T-cell activation [7].”
BackgroundGardner, J. K., Mamotte, C. D. S., Jackaman, C., & Nelson, D. J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.07.002 · Cited by 40
Metadata
- Authors
- Gardner, D., Jeffery, L. E., & Sansom, D. M.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 14
- Issue
- 9
- Pages
- 1985-1991
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1498940267
- Cited by
- 121
- References
- 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade. https://app.cochat.ai/papers/10.1111/ajt.12834
- The paper
- Gardner, D., Jeffery, L. E., & Sansom, D. M. (2014). Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade. American Journal of Transplantation. https://doi.org/10.1111/ajt.12834
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.